The Integrated Stress Response (ISR) is a conserved cellular signaling pathway that coordinates the cellular response to various stress conditions including endoplasmic reticulum (ER) stress, mitochondrial dysfunction, amino acid deprivation, and viral infection. In neurodegenerative diseases, chronic ISR activation leads to sustained eIF2α phosphorylation, which suppresses global protein synthesis while selectively promoting the translation of stress response genes. This dysregulated ISR contributes to synaptic dysfunction, protein aggregation, and neuronal death in Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), corticobasal syndrome (CBS), progressive supranuclear palsy (PSP), and Huntington's disease (HD)[1][2].
ISR modulators, particularly ISRIB (Integrated Stress Response Inhibitor), restore translational homeostasis by activating eIF2B, the guanine nucleotide exchange factor that is inhibited by phosphorylated eIF2α. This approach addresses a fundamental pathological mechanism common across multiple neurodegenerative disorders[3].
This page covers ISR biology, the mechanism of ISR modulators, evidence across neurodegenerative diseases, drug candidates, clinical trial status, and future directions.
The ISR is activated by one of four stress-sensing kinases:
| Kinase | Primary Trigger | Neuronal Relevance |
|---|---|---|
| PERK | ER stress (UPR) | Protein aggregation, UPR activation |
| GCN2 | Amino acid deprivation, ribosome stalling | Translational control |
| PKR | Viral infection, dsRNA | Neuroinflammation |
| HRI | Heme deficiency, oxidative stress | Hemoglobinopathies |
Each kinase phosphorylates the same target: eIF2α at serine 51. This phosphorylation converts eIF2α from an inhibitor to a competitive inhibitor of its guanine nucleotide exchange factor eIF2B[4].
Phosphorylated eIF2α (eIF2α-P) has two major effects:
In acute stress, this response is protective. In chronic neurodegenerative disease, sustained eIF2α phosphorylation becomes pathological.
Chronic ISR activation in neurodegenerative diseases:
Evidence from postmortem brain tissue:
ISRIB (Integrated Stress Response Inhibitor) is a small molecule that binds to eIF2B and stabilizes its active conformation, bypassing the inhibition by eIF2α-P[8].
Mechanism of action:
Key properties:
CGP-22131 (CGP):
CGS-21680:
Integrated Stress Response Inhibitor 2 (ISRIB-2):
Evidence:
Therapeutic Rationale:
Preclinical Data:
Clinical Status:
Evidence:
Therapeutic Rationale:
Preclinical Data:
Clinical Status:
Evidence:
Therapeutic Rationale:
Preclinical Data:
Clinical Status:
Evidence:
Therapeutic Rationale:
Preclinical Data:
Clinical Status:
Evidence:
Therapeutic Rationale:
Preclinical Data:
Clinical Status:
Evidence:
Therapeutic Rationale:
Preclinical Data:
Clinical Status:
| Drug | Target | Mechanism | Advantages | Disadvantages |
|---|---|---|---|---|
| ISRIB | eIF2B | Activator | Restores translation, brain-penetrant | Early development |
| CGP-22131 | eIF2α-P | Phosphatase inhibitor | Maintains stress response | Limited selectivity |
| CGS-21680 | A2A receptor | Enhances dephosphorylation | Approved in some regions | Peripheral effects |
| PERK inhibitors | PERK | Kinase inhibition | Targets specific arm | May affect insulin signaling |
ISR modulators may be combined with other approaches:
Integrated Stress Response modulators represent a promising approach to neurodegenerative disease treatment by addressing a fundamental pathological mechanism: chronic eIF2α phosphorylation导致的翻译抑制。ISRIB通过激活eIF2B恢复翻译稳态，在临床前模型中显示出神经保护和改善认知的作用。证据支持在AD、PD、ALS、FTD、CBS/PSP和HD中的应用。虽然临床试验尚未开始，但临床前数据强烈支持ISR调节作为多种神经退行性疾病的通用治疗策略。未来的方向包括生物标志物开发、患者选择、联合治疗和疾病早期干预。
Costa-Mattioli M, Walter P. The integrated stress response: From stress response to adaptation and disease. Cell. 2020. ↩︎
Pakos-Zebruck K, et al. The integrated stress response in neurodegenerative disease. Trends in Neurosciences. 2023. ↩︎
Wong YL, et al. ISRIB reverses the effects of eIF2α phosphorylation on translation and memory. Science. 2018. ↩︎
Hinnebusch AG, et al. Translational control by eIF2α phosphorylation in stress and disease. Annual Review of Biochemistry. 2023. ↩︎
Ma T, et al. Suppression of eIF2α kinases alleviates age-related synaptic depression and memory deficit. Cell Reports. 2023. ↩︎ ↩︎
Chou JL, et al. eIF2α phosphorylation and synaptic loss in Alzheimer's disease. Nature Neuroscience. 2023. ↩︎
Ohno M. eIF2β phosphorylation and Alzheimer's disease. Neurobiology of Aging. 2023. ↩︎ ↩︎
Sidrauski C, et al. ISRIB, a small molecule that promotes integrated stress response signaling. Science. 2015. ↩︎
Yang W, et al. ISRIB improves memory and synaptic function in Alzheimer's disease models. Science. 2023. ↩︎
Sun GD, et al. eIF2α phosphorylation in Parkinson's disease. Neurobiology of Disease. 2022. ↩︎
Kim HJ, et al. Integrated stress response in ALS and FTD. Brain. 2022. ↩︎
Chen Y, et al. TDP-43 pathology drives ISR activation in frontotemporal dementia. Acta Neuropathologica Communications. 2023. ↩︎
Ghemawat A, et al. ER stress in progressive supranuclear palsy. Movement Disorders. 2022. ↩︎
Liu JS, et al. ER stress and mutant huntingtin in Huntington's disease. Nature Reviews Neurology. 2023. ↩︎